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Abstract
Breast cancer is the most common cancer among women as metastasis is currently the main cause of mortality.
Breast cancer cells undergoing metastasis acquire resistance to death signals and increase of cellular motility and
invasiveness.
Plants are rich in polyphenolic compounds, many of them with known medicinal effects. Various phyto-polyphenols
have also been demonstrated to suppress cancer growth. Their mechanism of action is usually pleiotropic as they
target multiple signaling pathways regulating key cellular processes such as proliferation, apoptosis and differentiation.
Importantly, some phyto- polyphenols show low level of toxicity to untransformed cells, but selective suppressing
effects on cancer cells proliferation and differentiation.
In this review, we summarize the current information about the mechanism of action of some phyto-polyphenols that
have demonstrated anti-carcinogenic activities in vitro and in vivo. Gained knowledge of how these natural polyphenolic
compounds work can give us a clue for the development of novel anti-metastatic agents.
Keywords: Polyphenols, Breast cancer, Metastasis, Plant products, Resveratrol, EGCG, Kaempferol

Background
Breast cancer is the most common cancer in women, accounting for nearly 1 in 3 diagnosed cancers or 16% of
all female cancers. The incidence of breast cancer increases with age and is expected to escalate due to the
increase in life expectancy and the adoption of the Western lifestyle and rising rates of obesity. In spite of the advances in treatment, metastasis remain the main cause
of mortality in cancer patients contributing to 90% of
deaths from solid tumors (Gupta & Massagué 2006).
Natural products are used in traditional medicine over
the millennia for prevention and treatment of variety of
maladies, including cancer. Plants are rich in polyphenolic
compounds and many of these compounds have proven
beneficial effects in preventing the initiation and development of metastasis. Natural polyphenols have generally
pleiotropic effects in the cell, activating multiple signaling
pathways thus affecting many aspects of cellular fate, including cell apoptosis, proliferation, and differentiation. In
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this regard, it is worth studying the mechanism of action
of the natural polyphenols which can give us clues for the
development of new synthetic therapeutic molecules.
In this review, we summarize the main in vitro and in
vivo effects of some promising phyto-polyphenols that
have shown suppressing actions in the initiation and
progression of metastasis in breast cancer. Some of these
polyphenolic compounds are already in phase I, II, or III
clinical trials.

Breast cancer and metastasis
Epidemiology of breast cancer and metastasis

According to the American Cancer Society, the average
age at the time of breast cancer diagnosis is 61 years. Although, breast cancer predominates in women, about of
1% of all cases occur in men. Among the different ethnicities, breast cancer incidence rates are higher in
non-Hispanic Caucasian women compared to African
American women, but mortality rates are higher among
African Americans (32%) compared to non-Hispanic
Caucasians (24%). The most recent data for American
women diagnosed with breast cancer demonstrate survival rates of 89, 82, and 77% at 5, 10, and 15 years after
diagnosis (American Cancer Society, 2011).
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Human breast cancer is a heterogenous disease, which
can be classified into different groups depending on the
presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. The expression of these three
receptors strongly defines breast cancer behavior and treatment options. For example, HER2-positive breast cancers
are more aggressive in nature, but respond better to the
current therapy resulting in more favorable prognosis.
Much more challenging are the triple-negative breast cancers (TNBC) (ER/PR/HER2-negative), constituting between
10 and 20% of all breast cancers, which are characterized
by most aggressive behavior and lack effective therapies.
The prognosis in breast cancer strongly depends on the
presence or absence of metastasis in other organs. Today,
around 155,000 people in the United States live with
metastatic breast cancer and approximately 6–10% of all
newly diagnosed breast cancer patients are present with
metastatic disease at the time of diagnosis (American
Cancer Society, 2011) (NCI SEER 2018). Cancer metastases occur in 20–30% of all breast cancer cases and the median survival of metastatic breast cancer patients is on
average 3 years (O’Shaughnessy 2005).
Mechanism of breast cancer metastasis

Metastasis is a process involving interplay between
the cancer cells with their biological properties and
the host distant site providing specific microenvironment. Particular tumors have the affinity to spread in
particular organs. In 1889 Stephen Paget formulated
the so called “seed and soil” theory, which is based
on autopsy records of 735 women with breast cancer
(Paget 1989). According to this theory, the ‘seed’ is
the metastatic cell, and the ‘soil’ the metastatic site.
The basic idea behind the Paget’s theory is that in
order to metastasize, cancer cell must find a suitable
location bearing certain characteristics. Later, in 1928,
the American pathologist James Ewing challenged the
“seed and soil” theory, suggesting that the organ specific metastases could be explained by pure anatomical and mechanical circulatory patterns between the
primary tumor and the distant organs (Ewing 1928).
In fact, the compatibility between the cancer cells and
the host environment as well as the circulatory patterns play roles in the metastatic process. The determination which organ would be a target for cancer
invasion depends on the proximity of the tumor side
to the host organ and the connection between the
primary tumor and the metastatic site through the
vascular circulatory system. For example, breast cancer commonly metastasizes to bones or the ovaries.
In addition to using blood vessels, cancer cells (e.g.
breast carcinoma cells) can migrate by invading the
lymph nodes and using the lymphatic system, but

Page 2 of 17

they ultimately rely on the blood vessels to find their
way to the distant site.
To be able to metastasize the cancer cell must undergo
physiological changes and overcome numerous obstacles.
Generally, the metastatic process could be divided into several defined stages: (1) loss of cellular adhesion, (2) increase
of cellular motility and invasiveness, (3) entry and survival
in the circulation, (4) spread into distant tissue, and (5)
colonization of the distant site (Chambers et al. 2002). At
the beginning of the metastatic process, the primary tumor
needs to develop its own blood circulatory system which
also provides a route for tumor migration. Progression toward metastasis requires acquiring a resistance to cell death
signals accomplished by overexpression of anti-apoptotic
effector genes such as B-cell lymphoma 2 (BCL2), BCL-XL,
and X-linked inhibitor of apoptosis protein (XIAP) (Mehlen
& Puisieux 2006). Cancer cells undergoing metastasis are
characterized by increased expression of matrix metalloproteinases (MMPs), which proteolytically disrupt the protective basal membrane (MacDougall & Matrisian 1995).
Secreted proteases generate a variety of bioactive
cleavage peptides which further modulate cancer cell
migration, proliferation, survival, and tumor angiogenesis (Gupta & Massagué 2006). Once the cancer cells
enter the bloodstream, they increase the secretion of
proteins such as autocrine motility factor (AMF) and
motility-stimulating protein (MSP) which enable them
to survive the harsh conditions in the bloodstream
(Watanabe et al. 1991). Finally, the cancer cells extravasate from the circulation and enter the new site
where they form pre-angiogenic micrometastases
(Chambers et al. 2002).
Underlying event in metastasis is the epithelial-tomesenchymal transition (EMT), a process in which
particular cells lose their epithelial characteristics and
gain more mesenchymal-like features. During EMT
the cellular expression of cell adhesion molecules
(CAMs) decrease resulting in the formation of
spindle-shape morphology. EMT is a fundamental
process occurring during the embryonal development
(designated as Type I EMT), fibrosis or wound healing (or Type II EMT), but EMT also plays a key role
in cancer metastasis (also known as Type III EMT)
(Kalluri & Weinberg 2009). Main event during EMT
is the cleavage of the tight junction cell surface protein E-cadherin and inhibition of its expression by
SNAIL, SLUG, ZEB and TWIST transcription factors
accompanied by overexpression of N-cadherin, fibronectin, vimentin and other proteins (Peinado et al.
2007; Yang & Weinberg 2008). Cancer cells involved
in EMT undergo dynamic cytoskeletal rearrangements interacting intensively with the cell-matrix.
This process is governed by growth factors, which
directly or indirectly modulate plasma membrane
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proteases and focal adhesion disassembly (Gupta &
Massagué 2006).
Migratory cancer cells show elevated expression
MMPs, which are Calcium-dependent Zinc-containing
endopeptidases capable of degrading extracellular matrix
(ECM) proteins (Verma & Hansch 2007). There is a
strong correlation between the MMP expression and
cancer invasion and metastasis (Kanadaswami et al.
2005). MMPs participate in all stages of carcinogenesis
and are particularly important for tumor invasion
(McCawley & Matrisian 2000). Generally, overexpression
of MMPs is linked to higher metastasis capacity in many
tumors (Kanayama 2001; Saito et al. 2007; Castellano et
al. 2008; Lee et al. 2008). Expression of MMPs is induced
by growth factors (like epithelial growth factors [EGFs])
and receptor tyrosine kinase (RTKs) (such as EGF
receptor [EGFR]) involving PI3K (phosphatidylinositol-3-kinase) and NF-κB (nuclear factor kappa-light-chain-enhancer
of activated B cells) signaling cascades (Sen & Chatterjee
2011). Experimental results have shown that inhibition of
MMPs results in abolishment of tumor cell invasiveness
(Matrisian 1990; Rhee & Coussens 2002; Van den Steen et
al. 2002; Kanadaswami et al. 2005). For this reason, MMPs
are considered as important molecular targets for the anticancer therapy. Among the 23 currently known human
MMPs, the gelatinases (also known as type IV collagenases)
MMP-2 (s. gelatinase A) and MMP-9 (s. gelatinase B) play
key roles in the metastatic process. MMP-2 and -9 are suppressed by tissue inhibitors of metalloproteinases (TIMPs)
(Visse & Nagase 2003). There are four different TIMPs,
TIMP1, 2, 3, and 4, which bind non-covalently to MMP
thus inhibiting their expression (Brew & Nagase 2010).
NF-κB is a main player in the metastatic process because it is crucial regulator of cell proliferation and survival. NF-κB levels may predict the potential of the
tumor cells to metastasize (Jin et al. 2014). In resting
cells NF-κB exists in inactive form, located in the cytoplasm, bound to a family of inhibitory proteins referred
as IκB (inhibitors of κB). Members of IκB family include
IκB-α, IκB-β, IκB-γ, IκB-ε, IκB-ζ, p105, p100, and bcl3,
as IκB-α (also known as nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor-alpha
[NFKBIA]) is the most abundant among them. The control of NF-κB activity is carried out by IκB kinase (IKK)
kinases which include mitogen-activated protein kinase
kinase (MAPKK) family comprising of NF-κB-inducing
kinase (NIK) and MAPK/ERK kinase kinase (MEKK) 1,
2, and 3. When activated, NF-κB translocates to the nucleus where it serves as transcription factor regulating
genes controlling cell cycle, apoptosis, transformation,
and other processes. Constitutively active NF-κB is characteristic for many cancers. It protects the activation of
apoptotic signal by inhibiting p53 activity thus promoting the survival and neoplastic transformation of the
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cancer cells. The NF-κB signaling induces the expression
of a number of target genes involved in angio- and lymphangiogenesis among them the vascular endothelial
growth factor (VEGF). NF-κB directly induces the expression of urokinase-type plasminogen activator (uPA)
(Sliva et al. 2002), MMP-9, and chemokine receptor
CXCR4 (Helbig et al. 2003), which in turn results in promotion of ECM degradation and metastasis. The regulation of tumor metastasis by NF-κB is exerted by
reciprocal regulation of prometastatic (heparanase, etc.)
and antimetastatic (MMP-1, MMP-2, plasminogen activator inhibitor [PAI]-2, etc.) factors. Thus NF-κB is considered as an attractive candidate for metastasis
treatment. Number of developed therapeutic agents aim
to target NF-κB activity and function by different approaches such as induction of IκBα expression or prevention of its degradation, inhibition of NF-κB nuclear
translocation, suppression of NF-κB binding to DNA, inhibition of IKK functions, etc. (Wu & Kral 2005)
It is widely accepted that tumors are initiated by small
proportion of cancer stem cells (CSCs) that possess capacity for indefinite self-renewal. CSCs bear CD44+/
CD24−/low lineage characteristics and differentiate into
all other cellular phenotypes in the solid tumor as well
as they can initiate the formation of secondary tumors.
Recent experimental results suggest that microRNAs
(miRs) play a critical role in the formation of CSCs and
the acquisition of EMT (Li et al. 2010).
Role of tumor microenvironment in breast cancer
metastasis

Tumor is a complex structure comprised not only by
the neoplastic cells, but also by other cellular types of a
different origin, all of them residing in a specific ECM
microenvironment and communicating via soluble substances (Yu & Di 2017). Tumor-infiltrating lymphocytes
(TILs) are component of the tumor microenvironment
that play a major role in cancer development. Most of
the TILs are CD8+ T cells, CD4+ helper T cells (Th), and
CD4+ regulatory T cells (Tregs), as evidence suggest that
TILs are predictor of tumor outcome (Haanen et al.
2006). Huang et al. (2015) demonstrated that although
both, CD8+ and CD4+ cells have a role in cancer, during
breast cancer development the number of Th cells increase concomitantly with a change of their dominant
subsets from Th1 to Treg. On the other hand, CD8+
cells are inverse indicator of ER and PR status in the
breast tumor and may predict the clinical outcome
(Mahmoud et al. 2011). Another component of the
tumor microenvironment are the tumor-associated macrophages (TAMs) which are monocytes recruited by cytokines (such as the chemokine (C-C motif ) ligand 2
[CCL2]) from the peritumoral tissues or bone marrow.
TAMs can be divided into M1 and M2 machrophages, but
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studies also suggest that they may actually possess characteristics of both (Yu & Di 2017). Driven by interleukin
(IL)-4 and IL-10, tumor necrosis factor-alpha (TNFα),
macrophage colony-stimulating factor (M-CSF), or hypoxia, breast tumor microenvironment facilitate M1 differentiation into M2 (Laoui et al. 2011). Hypoxia of the white
adipose tissue may be induced by obesity and can further
lead to endocrine alterations promoting the secretion of
proinflammatory and angiogenic cytokines, and downregulating CCAAT-enhancer binding protein-alpha (C/EBPα)
thus inhibiting apoptosis and stimulating cell proliferation
(Ye et al. 2007; Khan et al. 2013). Since the cytokines released by the M1 macrophages in the early stages of cancer development have anti-proliferative effects on tumor
cells, the increased proportion of M2 macrophages in the
later stage of tumor development facilitate cancer growth
(Quail & Joyce 2013). Cancer-associated fibroblasts
(CAFs) are other component of the tumor microenvironment. It is suggested that these cells have heterogeneous
origin and derive from neighboring tissue fibroblasts, bone
marrow mesenchymal cells, epithelial cells undergoing
EMT or other cellular types (Shiga et al. 2015). CAFs directly modulate tumor progression and metastasis by secreting growth factors and cytokines that promote ECM
remodeling, cellular proliferation, EMT, and angiogenesis
(Cirri & Chiarugi 2011). Adipocytes are main component
of the mammary gland. In human, fat volume comprises
an average of 25% (7–56%) (Vandeweyer & Hertens 2002)
of the non-lactating and an average of 35% (9–54%) (Ramsay et al. 2005) of the lactating breast tissue. Mammary
adipose cells share characteristics with the subcutaneous
WAT adipocytes, but are distinctive from these cells
by their response to menstrual cycle and permanent
interactions with the surrounding epithelial cells
(Choi et al. 2017). Adipose cells are also a major
component of the tumor microenvitonment and are especially prominent in the breast tumors. Cancer-associated adipocytes (CAAs) are smaller than the non-tumor-associated
adipocytes and are highly secretory cells reprogrammed by
the tumor cells into dedifferentiated preadipocyte stage. The
role that CAAs play in tumor development is supported by
epidemiological observations of higher breast cancer incidence in obese postmenopausal women (Calle & Kaaks
2004) and associations of obesity with poorer clinical outcome (Reeves et al. 2007; Chan et al. 2014). CAAs affect
cancer cells proliferation, survival and invasion potential by
secreting various adipokines, lipids and reactive oxygen species (ROS) thus provoking ECM remodeling and metabolic
transformations (Choi et al. 2017; Nieman et al. 2013;
Berstein et al. 2007). Another component of the tumor
microenvironment are the endothelial cells (tumor endothelial cells [TEC]). These cells differ from the normal epithelial
cells in their responsiveness to EGF, VEGF and other growth
factors, and are associated with tumor cells adhesion,
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invasion, and metastasis (Hida et al. 2013). Besides of the
cellular components, ECM by itself plays a multifaceted role
in tumor development through biochemical and biomechanical mechanisms (Yu & Di 2017).

Phyto-polyphenols with promising inhibitory
effects on breast cancer metastasis
Polyphenols (s. polyhydroxyphenols) are class of chemical
compounds, broadly distributed in nature and characterized by the presence of phenol structures in their molecules. A vast group of polyphenols universally present in
the plant kingdom is the bioflavonoids. Comprising more
than 4000 distinct members, bioflavonoids are 15-Carbon
skeleton derivatives of beno-γ-pyrone (s. phenylchromone).
Flavonoids are divided into different classes that include
flavonols, glavans and proanthocyanidins, anthocyanidins,
flavanones, flavones, isoflavones, and noeflavonoids.
Phyto-polyphenols are integral part of the human diet.
They have been also used worldwide in traditional medicine
for thousands of years for their anti-bacterial, anti-viral,
anti-inflammatory, anti-allergic, and anti-thrombotic properties. The effects of phyto-polyphenols are usually pleiotropic, and many of these compounds have proven
anti-carcinogenic actions manifested by suppression of cancer cell transformation, differentiation, proliferation and invasiveness, angiogenesis and induction of apoptosis. The
anti-carcinogenic properties of the phyto-polyphenols can
be attributed to their direct effects on the activities of key
protein kinases controlling tumor cell proliferation and
apoptosis or to the suppression of MMP function. For example quercetin, fisetin or luteolin and other phyto-polyphenols inhibit the activity of protein kinase C (PKC). PKC
plays an important role in a variety of processes in cancer,
from tumor initiation and progression to inflammation and
T lymphocyte function. Genistein (Akiyama et al. 1987; Peterson & Barnes 1991; Pagliacci et al. 1994), luteolin (Huang
et al. 1999; Lee et al. 2002), quercetin (Agullo et al. 1997),
and butein (Yang et al. 1998) affect tumor development by
suppressing the activity of epidermal growth factor receptor
(EGFR) tyrosine kinase resulting in downstream effects on
number of substrates such as serine/threonine kinases,
mitogen-activated protein kinases (MAPKs), and rapidly accelerated fibrosarcoma kinases (RAFs) (Carpenter & Cohen
1990). Another protein tyrosine kinase that is targeted by
phyto-polyphenols (luteolin, quercetin, etc.) is the focal adhesion kinase (FAK) (Kanadaswami et al. 2005). FAK is a
key molecule in signaling pathways essential for the cell
cycle, survival, and motility.
Whole extracts or specific polyphenols derived from
green tea or grape vines have been shown to possess
anti-carcinogenic and anti-metastatic properties in multiple in vitro and in vivo studies. Extracts from peach (Prunus persica) (Noratto et al. 2014), olive (Olea europaea)
(Hassan et al. 2012), promegranate (Punica granatum)
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(Kim et al. 2002), evening primrose (Oenothera paradoxa)
(Lewandowska et al. 2013a; Lewandowska et al. 2013b),
the spotted (s. prostrate) spurge (Euphorbia suprina, (s. E.
maculata)) (Ko et al. 2015), Japanese quince (Chaenomeles
japonica) (Lewandowska et al. 2013c), Himalayan rhubarb
(Rheum emodi) (Kumar et al. 2015; Naveen Kumar et al.
2013) or Phyllanthus sp. (P. niruri, P. urinaria, P. watsonii,
P. amarus) (Lee et al. 2011), and others inhibit tumor
growth and suppress breast cancer metastasis.
Grape polyphenols

Grape vine plant consists of three main species: the
European grapes (Vitis vinifera), the North American
grapes (V. lanrusca and V. rotundifolia), and French hybrids. Grape vines belong to the Vitaceae family and
were domesticated as early as in the Neolithic period.
Grapes contain variety of polyphenolic compounds
largely anthocyanins, flavonols (catechin, epicatechin,
quercetin, procyanidin polymers), stilbenes (resveratrol),
and phenolic acids. Grape polyphenols are distributed
mostly in the seed, skin, leaf and the stem of the plant,
and in considerably less amount in its juicy middle section. Resveratrol, quercetin and catechin polyphenols
represent about 70% of the polyphenols present in the
grape plant and have the most potent anti-carcinogenic
activities (Damianaki et al. 2000). Importantly, grape
polyphenols are easily absorbed and metabolized in the
body in their intact form (Soleas et al. 2002). Experimental
data demonstrate that grape polyphenols have cardio- and
neuro-protective, anti-microbial (Lagneau et al. 1998;
Xia et al. 2010; Castillo-Pichardo et al. 2013),
anti-oxidant (Torres et al. 2002; Negro et al. 2003;
Makris et al. 2007) and variety of anti-carcinogenic
(anti-proliferative, pro-apoptotic, anti-invasive, anti-angiogenic, antioxidant, and cancer-preventive) properties
(Soleas et al. 2002; Asensi et al. 2002; Nifli et al. 2005;
Morré & Morré 2006; Hakimuddin et al. 2008; Gulati et
al. 2006; Kim et al. 2004; Dechsupa et al. 2007; Aggarwal
& Shishodia 2006; Kaur et al. 2009).
The suppressing effects of the grape polyphenols on
breast cancer initiation and cell growth are demonstrated
in multiple in vitro and in vivo systems (Singletary et al.
2003; Hakimuddin et al. 2004) (Singh et al. 2004) (Schlachterman et al. 2008). Using nude mice xenografted with
GFP-tagged highly metastatic ER-negative MDA-MB-468
breast cancer cells, Castillo-Pichardo et al. (2009) found
that low concentrations of grape polyphenols can inhibit
breast cancer metastasis initiation, specifically to liver and
bone. Experiments using BALB/c 4 T1 mammary xenograft mouse model showed that treatment with dietary
grape skin extracts in drinking water resulted in decrease
of lung metastasis incidence and stimulate cell survival
(Sun et al. 2012). Resveratrol, quercetin and catechin are
particularly important in estrogen receptor (ER)-positive
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breast tumors since they also act as selective estrogen receptor modulators (SERMs) (Harris et al. 2005). Grape
polyphenols exert their effects by modulating the activities
of Akt, extracellular-signal-regulated kinases (ERKs), and
MAPKs (Lu et al. 2009; Kaur et al. 2011; Sun et al. 2012).
These polyphenols inhibit the expression and activity of
EGFR1 and EGFR2 (s. HER2) (Azios & Dharmawardhane
2005; Fridrich et al. 2008), and elevated EGFR tumor expression is generally associated with higher cancer progression and metastasis (Buret et al. 1999). HER2 plays a
major role in the metastatic process and its overexpression
is often observed in metastatic cancers. Inhibition of
HER2 by grape polyphenols leads to inhibition of
phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian
target of rapamycin (mTOR) as well as activation of 5’
AMP-activated protein kinase (AMPK) – all of these enzymes are involved in the process of metastasis. Additionally, grape polyphenols upregulate forkhead box O1
(FOXO1) and IκBα thus inhibiting NF-κB activity
(Castillo-Pichardo et al. 2009).
Resveratrol

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid
and phytoalexin produced by grapes, peanuts, berries, and
the Japanese “Kojokon” (Polygonum cuspidatum) in response to injury or pathogen invasion (Burns et al. 2002).
Chemically, resveratrol is a precursor of a family of polymers named viniferins. It quickly enters the bloodstream
from the gastro-intestinal tract, reaching significant plasma
concentrations (Bhat et al. 2001). Resveratrol has been
used for centuries in the traditional Asian medicine since it
has broad range of effects, including anti-oxidant properties, modulation of lipid and lipoprotein metabolism,
anti-platelet aggregation, vaso-relaxation, wound-healing,
estrogenic activities and multiple anti-carcinogenic effects.
The anti-carcinogenic properties of resveratrol have
been demonstrated in many types of cancer including
those of the breast (Fig. 1) (Delmas et al. 2006; Busquets et al. 2007; Castillo-Pichardo et al. 2009). They
include tumor cell proliferation arrest, induction of
apoptosis, suppression of tumor cell mobility and migration, prevention of tumor-derived nitric oxide synthase expression, inhibition of tumor progression, etc.
(Jang et al. 1997; Nakagawa et al. 2001; Garvin et al.
2006) Resveratrol is a SERM that acts in different tissues as a pro- or anti-estrogen (Bowers et al. 2000).
Current literature exploring the in vivo doses of resveratrol needed to achieve beneficial anti-carcinogenic
effect is still not consolidated. In fact, low doses of reservatrol achievable from dietary sources (such as red wine)
seem to be sufficient in suppressing tumor growth
(Tessitore et al. 2000). Resveratrol might be an effective
chemopreventive agent and the mechanism behind this
effect includes direct inhibition of cyclooxygenase
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Fig. 1 Effects of reservatrol on breast cancer metastasis

(COX) activity and indirect suppression of ornithine
dacarboxylase (ODC) (Jang et al. 1997; Subbaramaiah et
al. 1999; Baur & Sinclair 2006). The effect of resveratrol
on COX and ODC activities could also explain its
anti-neovascularization and anti-angiogenic properties.
In vitro and in vivo studies have showed that resveratrol inhibits NF-κB and decreases its DNA binding
resulting in modulation of transcription of genes involved in tumor growth and metastasis (Tsai et al. 1999;
Banerjee et al. 2002; Benitez et al. 2009). Results from a
study using Sprague-Dawley rats where resveratrol was
given in the diet two weeks before vein injection with
the tumor-initiating agent 7,12-dimethylbenz(a)anthracene (DMBA) demonstrated that resveratrol acts as a
strong antioxidant and significantly induces apoptosis
with concomitant upregulation of TGFβ1 expression and inhibition of NF-κB in these carcinogen-challenged animals
(Chatterjee et al. 2011). Experiments using female FVB/N
HER2/neu transgenic mice spontaneously developing mammary tumors revealed significant reduction of lung metastases incidence after oral resveratrol supplementation
(Provinciali et al. 2005). Contrary to the previous results,
resveratrol was found to promote tumor growth and metastases incidence in immunocompromised mice grafted with
low-metastatic ERα-negative/ERβ-positive MDA-MB-231 or
highly-metastatic ERα/ERβ-negative MDA-MB-468 breast
cancer cells (Castillo-Pichardo et al. 2013). The reason for
the discrepancy between the experimental in vivo data may
be explained with the different protocols followed for drug
administration, the variable concentration of reservatrol
used or combination of multiple other factors.
Besides acting on tumor cells, reservatrol have modulating effects on tumor microenvironment. It induces CD8+
T cells antitumor immunity, decreases the percentage of
Tregs in the tumor, increases the levels of interferon-gamma

(IFNγ) and reduces those of IL-6, IL-10, and VEGF, as
shown in renal tumor model (Chen et al. 2015).
Reservatrol also reduces oxidative stress by acting as
a direct scavenger of ROX, by inhibiting NADPH
oxidase expression or xanthine oxidase activity
(Pelicano et al. 2004; Lin et al. 2000), or by increasing
sirtuin 1 (SIRT1) activity (Xu et al. 2012).
In summary, although the anti-carcinogenic and
cancer-preventive properties of resveratrol are proven in
multiple studies, the real efficacy of this compound in
vivo is still unclear. The clinical evidence for resveratrol
as an effective supplement for cancer prevention and
treatment is scarce as at this time there is very little clinical data for the efficacy of resveratrol in cancer
treatment.
Green tea polyphenols

Green tea is a product of leafs and the leaf buds of
Camellia sinensis plant that belongs to Theacea family. Green tea contains more than 200 bioactive compounds, among them polyphenols (catechins and
flavonols), alkaloids (caffeine), amino acid analogs
(theanine), vitamins, minerals, etc. Polyphenols are
the largest and most active group of chemical compounds
in the green tea comprising about 40% of the leave dry
weight. Polyphenols found in green tea include:
epigallocatechin-3-gallate (EGCG) (48.6%), epicathechin
gallate (ECG) (12.3%), epigallocatechin (EGC) (4.1%), epicatechin (EC) (4.1%), gallocatechin gallate (GCG) (1.8%),
gallocatechin (GC) (1.8%), catechin (1.2%), and gallic acid
(0.2%) (Slivova et al. 2005).
Green tea polyphenols demonstrate beneficial effects
in different pathological conditions including obesity,
diabetes and cancer. Polyphenols contained in the green
tea were also found to inhibit tumor growth and
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invasion of cancers such as leukemia, those of prostate,
lung, liver, and breast (Dreosti et al. 1997; Isemura et al.
1993) (Sartippour et al. 2001). In vitro studies using human MDA-MB-231 and MCF-7 breast cancer cells
showed downregulation of MMP-2 and -9, EGFR and
upregulation of TIMP-1 and -2, involvement of FAK/
ERK/NF-κB signaling pathways with concomitant inhibition of cellular invasion (Farabegoli et al. 2011; Sen et
al. 2010). Aqueous extract of green tea induced apoptosis and inhibited cell proliferation, migration and
invasion in metastasis-specific mouse mammary carcinoma 4 T1 cells in vitro. Green tea extract was effective in vivo in decreasing tumor weight and
significantly reduced lung and liver metastases incidence in female BALB/c mice bearing 4 T1 tumors
(Luo et al. 2014). In vivo, green tea polyphenols inhibited
the development and progression of lung, prostate,
esophagus, stomach, intestine, skin, and other cancers
(Katiyar & Mukhtar 1996; Yang et al. 2002). The induction
of apoptosis by green tea polyphenols was found to be
driven by mitochondria-targeted, caspase 3-executed
mechanism (Hsu et al., 2003). The anti-invasive properties
of the green tea polyphenols in breast cancer might be a
result of preventing the formation of molecular complexes
controlling cell adhesion and migration, specifically inhibition of activator protein-1 (AP-1) and NF-κB and consequent suppression of uPA secretion (Slivova et al. 2005).
Epidemiological studies, though inconclusive, suggest
possible cancer preventive action of the green tea polyphenols. Nevertheless the beneficial effect of tea consumption for cancer prevention or progression is
doubtful. In order to reach sufficient serum concentrations, high doses of polyphenols consumption are
needed. Still, regular consumption of green tea has been
associated with better prognosis in breast cancer patients (Nakachi et al. 1998) and possibly a decreased risk
of recurrence (Inoue et al. 2001).
Epigallocatechin gallate (EGCG)

EGCG is the ester of epigallocatechin and gallic acid and
it is the most abundant polyphenol in the green tea. In
addition to green tea, EGCG is present in trace amounts
in apples, plums, onions, hazelnuts, pecans, etc.
Experimental data demonstrate that EGCG inhibits
tumor cell proliferation, adhesion and invasion and induces apoptosis in variety of cancers including those of
the breast (Fig. 2) (Ahmad et al. 1997; Yang et al. 2009;
Shammas et al. 2006). Treatment of 4 T1 cells with
EGCG decreases Bcl-2 expression and mitochondrial
disruption thus releasing cytochrome C as well as upregulating Apaf-1, leading to the cleavage of caspase
3 and poly [ADP-ribose] polymerase (PARP) proteins
(Baliga et al. 2005). In the same study, oral administration of green tea polyphenols to 4 T1-xenografted BALB/c

Page 7 of 17

Fig. 2 Effects of epigallocatachin gallate (EGCG) on breast
cancer metastasis

mice resulted in reduction of tumor growth and lung metastasis incidence. The 67-kDa laminin receptor (67LR) has
been identified as an essential cell surface target for EGCG
action (Tachibana et al. 2004; Umeda et al. 2008). The
mechanism of the tumor-suppressive and anti-metastatic actions of EGCG is a result of involvement of Akt/eNOS/NO/
cGMP/PKCδ signaling cascade (Kumazoe et al. 2013). Similarly to other polyphenolic compounds, the effect of EGCG
in cancer cells is pleiotropic. It inhibits the activities of PTKs
(EGFR, FGFR, PDGFR, HER2/neu tyrosine kinases) and
Akt kinase (Liang et al. 1997; Pianetti et al. 2002) via
STAT3, PI3K, mTOR, and NF-κB signaling pathways
(Masuda et al. 2002; Van Aller et al. 2011). Results
from in vitro study by using MDA-MB-231 cells demonstrated that EGCG modulates cell matrix adhesion
molecules and growth factor receptors through FAK/ERK
signaling pathway mechanism (Sen & Chatterjee 2011).
IGCG also inhibits the expression and activities of
MMP-2 and -9 (Sen et al. 2009; Yang et al. 2005;
Sen et al. 2010) (Farabegoli et al. 2011), and this
seems to be the main driver for its anti-metastatic
actions (Yang & Wang 1993). The inhibition of
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MMPs can be explained by the fact that EGCG suppresses FAK, PI3K, and ERK which further leads to
downregulation of EGF (Sen & Chatterjee 2011). In
addition, the suppression of MMPs involves epigenetic induction of TIMP-3 levels through inhibition of
the enhancer of zeste homolog 2 (EZH2) and class I
histone deacetylases (HDACs) (Deb et al. 2014).
Short-term supplementation with the active compounds
in green tea in men with prostate cancer showed that
EGCG significantly reduces serum levels of VEGF
(McLarty et al. 2009). Based on experimental data, it appears that plasma concentrations of EGCG comparable to
those observed in regular green tea consumers are sufficient to inhibit MMPs and thus to affect negatively the invasion potential and metastasis in breast cancer patients
(Garbisa et al. 2001).
In addition of suppressing tumor growth, ECGC was
found to modulate tumor microenvironment by reducing TAM infiltration (Jang et al. 2013). In the same
study, ex vivo incubation of TAM with exosomes from
ECGC-treated mouse mammary tumor 4 T1 cells
skewed macrophages from tumor-promoting M2-like
to tumor-inhibitor M1-like phenotype (Jang et al.
2013). Further, EGCG targets tumor microenvironment by preventing and reversing the advancement of
fibroblast-mediated effects by inhibiting signaling cascades downstream of TGFβ (Gray et al. 2014).
Other phyto-polyphenols

Along with the above discussed phyto-polyphenols, a number of other compounds have been investigated for their
anti-carcinogenic properties, including anti-metastatic actions. Plants rich in these polyphenolic compounds have
been used for centuries in culinary and traditional medicine.
Kaempferol

Kaempferol (3,5,7-Trihydroxy-2-(4-hydroxyphenil)-4H-chromen-4-one) is a naturally occurring flavonol in broad range
of plants from Pteridophyta, Pinophyta and Angiospermae
divisions. Among the commonly consumed foods containing kaempferol are grapes, green tea, apples, tomatoes, potatoes, onions, broccoli, squash, Brussels sprouts, cucumbers,
lettuce, green beans, peaches, blackberries, raspberries,
spinach, etc. Kaempferol is actively absorbed in the
small intestine and can be found in the plasma in nanomolar concentrations (Calderón-Montaño et al. 2011). This
polyphenol is easily metabolized in the liver and is delivered
to various other organs in the form of glucuronides and
sulfoconjugates (Calderón-Montaño et al. 2011).
To date, kaempferol has been shown to exert a variety
of effects including antioxidant, anti-inflammatory,
anti-microbial, anxiolytic, anti-allergic as well as
anti-carcinogenic and cancer preventive activities
(Calderón-Montaño et al. 2011). Multiple in vitro
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and in vivo studies demonstrated that kaempferol has
pleiotropic effects in cancer targeting cancer cell proliferation, apoptosis and mobility, tumor growth,
angiogenesis and metastasis (Fig. 3) (Kim & Choi
2013; Calderón-Montaño et al. 2011; Boam 2015; Srinivas 2015). Kaempferol is an endocrine-disruptor
that influences the activity of ER, having both, estrogenic and anti-estrogenic properties (Calderón-Montaño et al. 2011). This makes kaempferol potentially
useful in ER-positive breast cancers, where it suppresses tumor growth by ER-dependent mechanism
(Oh et al. 2006).
Kaempferol interacts with major signaling pathways
such as ERK1/2 (Aiyer et al. 2012), MAPK (Li et al.
2015), and p53 (Calderón-Montaño et al. 2011), and is a
potential anti-metastasis agent. It inhibits the invasion,
adhesion, and migration of U-2 osteosarcoma cells
(Chen et al. 2013). Anti-metastatic effects of kaempferol
were observed in SCC4 oral cancer cells where it downregulated MMP-2 and TIMP-2 mRNA and protein expression
by suppressing c-Jun activity (Lin et al. 2013). Recent study
found that kaempferol inhibits MDA-MB-231 breast cancer cell adhesion, migration and invasion, and reduces lung
metastasis incidence in mice (Li et al. 2015).
The mechanisms behind the anti-metastatic effects of
kaempferol include supression of MMPs (MMP-2 and
MMP-9) and uPA expression and activity via ERK, p38,
JNK, and MAPK signaling (Chen et al. 2013). Kaempferol inhibits the translocation of the MAPK upstream
regulator PKCδ from the cytoplasm to the plasma membrane where it is physiologically active, thus suppressing
MAPK signaling pathway (Li et al. 2015). Another mechanism by which kaempferol suppress metastasis is by
inhibiting VEGF production as demonstrated in ovarian
cancer OVCAR-3 cells in vitro (Luo et al. 2008). In the
same cell line, kaempferol was also shown to downregulate cMyc and promote apoptosis (Luo et al. 2010). Additionally, kaempferol inhibits lymphangiogenesis, which
is an integral step in the metastatic process. It reduces
the density of tumor-associated lymphatic vessels as well
as the incidence of lymph node metastases in breast cancer xenograft models in a VEGFR2/3 kinase manner
(Astin et al. 2014).
Curcumin

Curcumin (s. diferuloylmethane, E100 (Natural Yellow 3))
((1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a natural diarylheptanoid polyphenol
derived from turmeric plant (Curcuma longa) belonging
to the ginger family (Zingiberaceae). Turmeric is common
ingredient of the traditional Indian cuisine (main ingredient of curry) as well as it is used worldwide as a food additive for coloring (bright-yellow agent E100). Additionally,
turmeric is known for its medicinal properties.
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Fig. 3 Effects of kaempferol on breast cancer metastasis

Powdered turmeric underground stems (rhizomes)
have been used for more than 6000 years for treating
broad range of conditions related to inflammation, allergies, parasitic infections, respiratory diseases, diabetes, neurodegenerative diseases and many others.
Turmeric-derived curcumin has also well established
anti-carcinogenic activities on cell transformation,
proliferation, apoptosis, survival, invasion, metastasis,
adhesion as well as angiogenesis. The anti-carcinogenic
effects of curcumin have been demonstrated in different
studies on hematogenous, multiple myeloma, glioblastoma,
skin, head and neck, lung, colon, prostate, breast, and other
types of cancer (Bachmeier et al. 2007; Kuo et al. 1996; Sung
et al. 2009; Dhandapani et al. 2007; Limtrakul et al. 1997;
Wilken et al. 2011; Moghaddam et al. 2009; Chen et al.
1999; Kawamori et al. 1999; Johnson & Mukhtar 2007;
Chendil et al. 2004; Mehta et al. 1997; Huang et al. 1998;
Killian et al. 2012).
Curcumin is poorly metabolized and extensively excreted. It can be found in low concentrations in plasma
and variety of tissues (Anand et al. 2007). Despite its lower
bioavailability, curcumin in low concentrations has been
shown to possess toxicity selectively to cancer, but not to
untransformed cells (Syng-Ai et al. 2004). For example,
experimental data showed that human multidrug-resistant
breast cancer MCF-7/TH cells are approximately 3.5-fold

more sensitive to curcumin than the non-carcinogenic
epithelial MCF-10A cells (Ramachandran & You 1999).
The anti-carcinogenic properties of curcumin are
pleiotropic and are based on its effects on both, the
tumor cells and the tumor microenvironment. For
example, curcumin can modulate inflammatory
pathways and tumor progression and metastasis, affecting tumor cell survival, proliferation, and invasiveness
(Gupta et al. 2010). Curcumin as well as other plant-derived
natural polyphenols such as EGCG or resveratrol, induce
epigenetic changes (inhibition of DNA methyltransferases (DNMTs), regulation of histone acetyltransferases
(HATs) and HDACs, or microRNA modulation)
(Gonwa et al. 1989) that lead to suppression of EMT
and metastasis (Bandyopadhyay 2014; Bachmeier et al.
2007; Kunnumakkara et al. 2008).
The anti-metastatic action of curcumin involves
inhibition of MMP-2, − 9, and MT1-MMP (Ohashi et
al. 2003; Kim et al. 2012) (Fig. 4). Curcumin acts as specific supressor of p300/CREB-binding protein and affects
major signalling pathways, protein tyrosine kinases and
cytokines such as MAPK (Kim et al. 2012), JAK2/STAT3,
Src/Akt (Saini et al. 2011), c-Jun/AP-1 (Collett &
Campbell 2004), PKC (Garg et al. 2008), sonic hedgehog
(Elamin et al. 2010), CXCL1 and 2 (Killian et al. 2012), etc.
It also inhibits HDACs 1, 3, and 8 and HATs enzyme
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Fig. 4 Effects of curcumin on breast cancer metastasis

activities and modulates chromatin modification
(Balasubramanyam et al. 2004; Reuter et al. 2011). In
addition, curcumin suppresses NF-κB signaling by
negative modulation of IKK, either directly or through
action of its upstream activators (Bharti et al. 2003;
Jobin et al. 1999), preventing in such a way phosphorylation of IκB (Plummer et al. 1999). Curcumin
abolishes the DNA binding of NF-κB and inhibits reporter gene expression in H1299 non-small cell lung
carcinoma cell line, thus downregulating MMP-9
activation (Shishodia et al. 2003). In mice, where
MDA-MB-231 breast cancer cells were injected intracardiac, oral curcumin administration significantly reduced the number of lung metastases (Bachmeier et
al. 2007). This effect was most likely a result of inhibition of NF-κB activity and transcriptional downregulation of AP-1 and downregulation of cyclin D1,
COX-2, and MMP-9, which further leads to inhibition
of the breast cancer cell metastasis (Aggarwal et al.
2005; Kim et al. 2012).
Chronic inflammation is considered to be a major factor
in tumor progression. For example, chronic prostatitis,
chronic obstructive pulmonary disease, inflammatory
bowel disease or chronic pancreatitis – all represent risk
factors for developing prostate, lung, colon or pancreatic
cancer. Curcumin inhibits chronic inflammation by disrupting the feedback loop between NF-κB and the
pro-inflammatory cytokines, CXCL-1 and -2 (reviewed by
Bandyopadhyay (Bandyopadhyay 2014)).

By inhibiting NF-κB signaling, curcumin suppresses metastasis in the very early stages of EMT. In lipopolysaccharide (LPS)-induced EMT in MCF-7 and MDA-MB-231
cells, curcumin downregulated the expression of vimentin
and upregulated those of E-cadherin as well as inhibited
LPS-induced morphological transformation of the cells
through inactivation of NF-κB-SNAIL signaling pathway
(Huang et al. 2013).
Curcumin acts also as a phytoestrogen (Bachmeier
et al. 2010). The anti-proliferative effects of curcumin
were found to be estrogen-dependent in ER-positive
MCF-7 counteracting the estrogen responsive element
(ERE)-CAT activities of estradiol (Shao et al. 2002).
HER2/neu-positive or tamoxifen-resistant breast tumors are associated with specific microRNA signature, including overexpression of miR-181 (Miller et
al. 2008; Lowery et al. 2009). In breast cancer, curcumin was shown to inhibit metastasis by inducing the
expression of miR-181b and downregulatinng those of
CXCL-1 and -2 (Kronski et al. 2014).
A variety effects on tumor microenvironment were described after curcumin treatment. In colon cancer, curcumin interacts with the stromal fibroblasts in the colon
tumor microenvironment thus suppressing their crosstalk
with CSCs (Buhrmann et al. 2014). Treatment with
curcumin-polyethylene glycol conjugate (an amphiphilic
curcumin-based micelle) suppressed the percentage of
myeloid-derived suppressor cells (MDSCs), which was
suggested to be the reason behind the observed
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inhibition of Treg and the activation of the effector T-cells
(Lu et al. 2016). Combination of curcumin and ECGC inhibits colorectal carcinoma microenvironment-induced
angiogenesis by activating JAK/STAT3/IL-8 signaling
pathway (Jin et al. 2017). Curcumin downregulates
the expression of VEGF as shown in prostate cancer
cells (Gupta et al. 2013) and blocked IL-1 and VEGF
expression in chondrosarcoma cells (Kalinski et al. 2014).
Currently, curcumin is an object of more than 120
clinical trials evaluating its effects against different
maladies including cancer.
Honokiol

Honokiol is a biphenolic lignan with bioactive para-allyl
and ortho-allyl phenolic groups, a product of Magnolia
sp. (M. biondii, M. obovate, and M. officinalis) that demonstrates promising actions on tumor metastases. Bark
or seed cones of magnolia plants has been used for
centuries in the traditional Asian medicine for its
anti-inflammatory, antithrombotic, anxiolytic, antidepressant, antispasmodic, antioxidant, and antibacterial
effects and its protective action against hepatotoxicity,
neurotoxicity and angiopathy (Fried & Arbiser 2009; Lee
et al. 2011). The anti-carcinogenic activities of honokiol
range from tumor suppression, pro-apoptotic and

Fig. 5 Effects of honokiol on breast cancer metastasis

Page 11 of 17

anti-angiogenic effects, and inhibition of cancer metastasis incidence by effects on tumor proliferation, migration
and invasion. These properties have been demonstrated
in various cancer types such as sarcoma (Nagase et al.
2001; Su et al. 2013), multiple melanoma (Ishitsuka et al.
2005), leukemia (Hirano et al. 1994; Hibasami et al.
1998; Battle et al. 2005), lung (Yang et al. 2002; Singh &
Katiyar 2013), skin (Konoshima et al. 1991), pancreas
(Bai et al. 2003), ovary (Li et al. 2008), prostate
(Shigemura et al. 2007), colorectal (Wang et al. 2004),
breast (Nagalingam et al. 2012; Avtanski et al. 2014), and
other cancers (Nagase et al. 2001; Garcia et al. 2008;
Deng et al. 2008; Chen et al. 2011; Chang et al. 2013).
One important characteristic of honokiol is that it easily
crosses the blood-brain barrier and achieves significant
serum concentrations because of its hydrophobic and
lipophilic properties (Wang et al. 2011; Lin et al. 2012;
Woodbury et al. 2013).
Honokiol has pleiotropic effects in the cells (Fig. 5),
including modulation of NF-κB (Tse et al. 2005; Lee
et al. 2005; Ahn et al. 2006; Sheu et al. 2008; Arora
et al. 2011), MAPK (Kim et al. 2012; Zhang et al.
2014), STAT3 (Rajendran et al. 2012; Avtanski et al.
2014), Akt [238,], VEGF (Wen et al. 2015), ERK (Zhu et
al. 2014; Yeh et al. 2016), s-Scr (Park et al. 2009), and
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other major signaling pathways (Fried & Arbiser 2009).
For example, in SVR angiosarcoma cells, honokiol induces
apoptosis by suppressing the phosphorylation of ERK,
Akt, and c-Src (Bai et al. 2003). In addition to its
anti-proliferative properties, honokiol inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) and suppresses angiogenesis in
zebrafish angiogenesis model (Zhu et al. 2011). Honokiol
downregulates IKK activation and thus inhibits NF-κB signaling pathway and MMP-9, TNFα, IL-8, ICAM-1, and
MCP-1 expression (Tse et al. 2005; Lee et al. 2005; Ahn et
al. 2006; Sheu et al. 2008). It also inhibits the migration
and invasion of MCF-7 and MDA-MB-231 cells by upregulating the activity of liver kinase B1 (LKB1) leading to activation of AMP-activated protein kinase (AMPK)
(Nagalingam et al. 2012). In vivo, honokiol inhibited
tumor growth of MDA-MB-231 cells-xenografted nude
mice by blocking breast cancer cellular proliferation
(Nagalingam et al. 2012). Our in vitro and in vivo studies
revealed that honokiol inhibits EMT of breast cancer cells
by suppressing STAT3 signaling resulting in repression of
ZEB1 expression and its recruitment on the E-cadherin promoter (Avtanski et al. 2014). Honokiol modulated microRNA profile in the breast cancer cell, specifically amplifying
miR-34a expression in a STAT3-dependent manner, inhibiting Wnt1-metastatic-associated protein 1 (MTA1)-β-catenin
signaling axis (Avtanski et al. 2015a). The mechanism behind the effects of honokiol on EMT and breast cancer migration involves induction of SirT1, SirT3 and miR-34a
expression and cytoplasmic localization of LKB1 (Avtanski
et al. 2015b).
Aside from directly targeting tumor cells, honokiol
was also demonstrated to have effects on tumor microenvironment. Honokiol decreased desmoplasia in pancreatic tumor xenografts, as characterized by reduced
secretion of extracellular matrix protein (collagen I) and
suppressed myofibroblast marker α-smooth muscle actin
(α-SMA) immunostaining (Averett et al. 2016). Findings
from the same study revealed an inhibitory effect of
honokiol on C-S-C chemokine receptor type 4 (CXCR4)
signaling, which is known to play an important role in
the crosstalk between the tumor and the stromal cells.

Conclusions
Nature is abundant in chemicals with potential therapeutic effects that are worth studying. A variety of polyphenols from plant origin demonstrate pleiotropic
therapeutic properties against a broad range of pathological conditions, including different types of cancer.
Such polyphenolic compounds can be viewed as promising candidates for supplements to the traditional cancer
prevention and treatment modalities as well as a basis
for designing novel synthetic drugs. Naturally derived
plant polyphenols have been demonstrated to inhibit
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metastasis initiation and progression by targeting both,
cancer cells and cancer microenvironment. Novel strategies for targeting metastasis aim to modulate the levels
of specific microRNAs that play a role in the transformation of the malignant cells. This approach could be
used against CSCs or cells undergoing EMT that are
typically drug resistant (Li et al. 2010). Importantly,
some phyto-polyphenolic compounds have been shown
to exert beneficial effects through direct modulation of
specific microRNAs at low concentrations.
Natural polyphenolic compounds are usually characterized by low level of toxicity, but main disadvantage is
their poor bioavailability and weak resorption reaching.
In this regard, new strategies for target-specific delivery
have been experimentally developed and proven to be effective. Recent advances in nano-medicine open the
doors for the development of vehicles for drug delivery
with long-circulation that can be used to target transformed cells. Polyphenolic compounds administered by
traditional methods are not always effective because of
they are poorly absorbed and extensively excreted. But
the chemopreventive efficacy of these polyphenols can
be significantly improved by encapsulating them into
nonoparticles. Thus, integration of various disciplines
such as biochemistry, molecular biology, chemistry, and
nanotechnology could contribute to the development of
novel therapies against breast cancer methastasis.
This paper is dedicated to the memory of Rumiana
Cherneva, who lost the battle with breast cancer.
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